Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
Georgina V. Long(The University of Sydney), Helen Rizos(Macquarie University)
Cited by 55
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906